The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Determinants of dopaminergic neuron loss in Parkinson's disease
Open accessAbstract
The cardinal motor symptoms of Parkinson's disease (PD) are caused by the death of dopaminergic neurons in the substantia nigra pars compacta (SN c). Alpha‐synuclein (aSYN) pathology and mitochondrial dysfunction have been implicated in PD pathogenesis, but until recently it was unclear why SN c dopaminergic neurons should be particularly vulnerable to these two types of insult. In this brief review, the evidence that SN c dopaminergic neurons have an anatomical, physiological, and biochemical phenotype that predisposes them to mitochondrial dysfunction and synuclein pathology is summarized. The recognition that certain traits may predispose neurons to PD‐linked pathology creates translational opportunities for slowing or stopping disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Rockenstein, E., Nuber, S., Overk, C. R., Ubhi, K., Mante, M., Patrick, C., Adame, A., Trejo-Morales, M., Gerez, J., Picotti, P., et al. (2014) · Brain · doi:10.1093/brain/awu057 · Cited by 238
RetractedPolazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
The action potential in mammalian central neurons
Bean, B. P. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2148 · Cited by 1,785
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & -Y. Lee, V. M. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,546
In vivo demonstration that α-synuclein oligomers are toxic
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100976108 · Cited by 1,463
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Self-citationParkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Self-citationα-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., & Khrapko, K. (2006) · Nature Genetics · doi:10.1038/ng1778 · Cited by 887
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Self-citationPrion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Self-citationAutophagy gone awry in neurodegenerative diseases
Wong, E., & Cuervo, A. M. (2010) · Nature Neuroscience · doi:10.1038/nn.2575 · Cited by 815
MAM: more than just a housekeeper
Hayashi, T., Rizzuto, R., Hajnoczky, G., & Su, T.-P. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.12.002 · Cited by 787
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 753
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Recasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
ΔΨ m ‐Dependent and ‐independent production of reactive oxygen species by rat brain mitochondria
Votyakova, T. V., & Reynolds, I. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00548.x · Cited by 601
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
Pacelli, C., Giguère, N., Bourque, M.-J., Lévesque, M., Slack, R. S., & Trudeau, L.-É. (2015) · Current Biology · doi:10.1016/j.cub.2015.07.050 · Cited by 530
Axon degeneration in Parkinson's disease
Burke, R. E., & O'Malley, K. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.011 · Cited by 493
Defects in trafficking bridge Parkinson’s disease pathology and genetics
Abeliovich, A., & Gitler, A. D. (2016) · Nature · doi:10.1038/nature20414 · Cited by 462
Cholinergic interneuron characteristics and nicotinic properties in the striatum
Zhou, F., Wilson, C. J., & Dani, J. A. (2002) · Journal of Neurobiology · doi:10.1002/neu.10150 · Cited by 444
Living on the edge with too many mouths to feed: Why dopamine neurons die
Bolam, J. P., & Pissadaki, E. K. (2012) · Movement Disorders · doi:10.1002/mds.25135 · Cited by 436
Robust Pacemaking in Substantia Nigra Dopaminergic Neurons
Guzman, J. N., Sánchez-Padilla, J., Chan, C. S., & Surmeier, D. J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2519-09.2009 · Cited by 411
Self-citationSubthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection
Rodriguez, M. C., Obeso, J. A., & Olanow, C. W. (1998) · Annals of Neurology · doi:10.1002/ana.410440726 · Cited by 396
Changes in network activity with the progression of Parkinson's disease
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Axis of ageing: telomeres, p53 and mitochondria
Sahin, E., & DePinho, R. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3352 · Cited by 345
Burden of illness in Parkinson's disease
Huse, D. M., Schulman, K., Orsini, L., Castelli‐Haley, J., Kennedy, S., & Lenhart, G. (2005) · Movement Disorders · doi:10.1002/mds.20609 · Cited by 335
C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction
Lautenschläger, J., Stephens, A. D., Fusco, G., Ströhl, F., Curry, N., Zacharopoulou, M., Michel, C. H., Laine, R., Nespovitaya, N., Fantham, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03111-4 · Cited by 334
Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., & Lee, M. K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5368-11.2012 · Cited by 323
Puopolo, M., Raviola, E., & Bean, B. P. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4341-06.2007 · Cited by 319
The neuropathology of genetic Parkinson's disease
Poulopoulos, M., Levy, O. A., & Alcalay, R. N. (2012) · Movement Disorders · doi:10.1002/mds.24962 · Cited by 311
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration
Walsh, D. M., & Selkoe, D. J. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.13 · Cited by 294
MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease
Przedborski, S., Tieu, K., Perier, C., & Vila, M. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041771.66775.d5 · Cited by 287
Excitotoxicity and nitric oxide in parkinson's disease pathogenesis
Beal, M. F. (1998) · Annals of Neurology · doi:10.1002/ana.410440716 · Cited by 283
Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S., & Selkoe, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545749 · Cited by 279
Prying into the Prion Hypothesis for Parkinson's Disease
Brundin, P., & Melki, R. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1788-16.2017 · Cited by 275
L‐type calcium channel blockers and Parkinson disease in Denmark
Ritz, B., Rhodes, S. L., Qian, L., Schernhammer, E., Olsen, J. H., & Friis, S. (2010) · Annals of Neurology · doi:10.1002/ana.21937 · Cited by 273
Aging and Parkinson's disease: Different sides of the same coin?
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.27037 · Cited by 268
Khaliq, Z. M., & Bean, B. P. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0143-10.2010 · Cited by 261
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
Ilijic, E., Guzman, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 259
Self-citationUchihara, T., & Giasson, B. I. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1485-1 · Cited by 249
Calpain-Cleavage of α-Synuclein
Dufty, B. M., Warner, L. R., Hou, S. T., Jiang, S. X., Gomez-Isla, T., Leenhouts, K. M., Oxford, J. T., Feany, M. B., Masliah, E., & Rohn, T. T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061232 · Cited by 241
Wallace, B. A., Ashkan, K., Heise, C. E., Foote, K. D., Torres, N., Mitrofanis, J., & Benabid, A.-L. (2007) · Brain · doi:10.1093/brain/awm137 · Cited by 235
Thakur, P., Breger, L. S., Lundblad, M., Wan, O. W., Mattsson, B., Luk, K. C., Lee, V. M. Y., Trojanowski, J. Q., & Björklund, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710442114 · Cited by 233
The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work
Balaban, R. S. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.05.011 · Cited by 232
Futami, T., Takakusaki, K., & Kitai, S. T. (1995) · Neuroscience Research · doi:10.1016/0168-0102(94)00869-h · Cited by 230
Use of antihypertensives and the risk of Parkinson disease
Becker, C., Jick, S. S., & Meier, C. R. (2008) · Neurology · doi:10.1212/01.wnl.0000303818.38960.44 · Cited by 230
Mitochondrial DNA Depletion in Respiratory Chain–Deficient Parkinson Disease Neurons
Grünewald, A., Rygiel, K. A., Hepplewhite, P. D., Morris, C. M., Picard, M., & Turnbull, D. M. (2016) · Annals of Neurology · doi:10.1002/ana.24571 · Cited by 229
Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading
Iljina, M., Garcia, G. A., Horrocks, M. H., Tosatto, L., Choi, M. L., Ganzinger, K. A., Abramov, A. Y., Gandhi, S., Wood, N. W., Cremades, N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524128113 · Cited by 225
Lysosomal cell death mechanisms in aging
Gómez-Sintes, R., Ledesma, M. D., & Boya, P. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.009 · Cited by 216
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Dryanovski, D. I., Guzman, J. N., Xie, Z., Galteri, D. J., Volpicelli-Daley, L. A., Lee, V. M. Y., Miller, R. J., Schumacker, P. T., & Surmeier, D. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5311-12.2013 · Cited by 212
Self-citationSeeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
Roberts, H., & Brown, D. (2015) · Biomolecules · doi:10.3390/biom5020282 · Cited by 212
α‐synuclein assemblies sequester neuronal α3‐Na + /K + ‐ ATP ase and impair Na + gradient
Shrivastava, A. N., Redeker, V., Fritz, N., Pieri, L., Almeida, L. G., Spolidoro, M., Liebmann, T., Bousset, L., Renner, M., Léna, C., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591397 · Cited by 212
Nedergaard, S., Flatman, J. A., & Engberg, I. (1993) · The Journal of Physiology · doi:10.1113/jphysiol.1993.sp019742 · Cited by 211
Burke, W. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00090-1 · Cited by 211
Autosomal dominant Parkinson's disease caused by SNCA duplications
Konno, T., Ross, O. A., Puschmann, A., Dickson, D. W., & Wszolek, Z. K. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.007 · Cited by 210
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199
Reeve, A. K., Ludtmann, M. H., Angelova, P. R., Simcox, E. M., Horrocks, M. H., Klenerman, D., Gandhi, S., Turnbull, D. M., & Abramov, A. Y. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.166 · Cited by 198
Ca2+ is a key factor in α-synuclein-induced neurotoxicity
Angelova, P. R., Ludtmann, M. H. R., Horrocks, M. H., Negoda, A., Cremades, N., Klenerman, D., Dobson, C. M., Wood, N. W., Pavlov, E. V., Gandhi, S., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.180737 · Cited by 194
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
Zharikov, A. D., Cannon, J. R., Tapias, V., Bai, Q., Horowitz, M. P., Shah, V., El Ayadi, A., Hastings, T. G., Greenamyre, J. T., & Burton, E. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci64502 · Cited by 186
Impaired intracellular trafficking defines early Parkinson's disease
Hunn, B. H. M., Cragg, S. J., Bolam, J. P., Spillantini, M.-G., & Wade-Martins, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.009 · Cited by 184
Mitochondria and neuronal glutamate excitotoxicity
Nicholls, D. G., & Budd, S. L. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00123-6 · Cited by 171
The coming crisis: Obtaining care for the growing burden of neurodegenerative conditions
Dorsey, E. R., George, B. P., Leff, B., & Willis, A. W. (2013) · Neurology · doi:10.1212/wnl.0b013e318293e2ce · Cited by 167
Lessons from the rotenone model of Parkinson's disease
Greenamyre, J. T., Cannon, J. R., Drolet, R., & Mastroberardino, P.-G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.12.006 · Cited by 166
Morikawa, H., & Paladini, C. A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.023 · Cited by 162
Protection of nigral cell death by bilateral subthalamic nucleus stimulation
Temel, Y., Visser-Vandewalle, V., Kaplan, S., Kozan, R., Daemen, M. A. R. C., Blokland, A., Schmitz, C., & Steinbusch, H. W. M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.082 · Cited by 161
Use of Calcium Channel Blockers and Parkinson’s Disease
Pasternak, B., Svanström, H., Nielsen, N. M., Fugger, L. H., Melbye, M., & Hviid, A. P. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr362 · Cited by 159
Raised calcium promotes α-synuclein aggregate formation
Nath, S., Goodwin, J., Engelborghs, Y., & Pountney, D. L. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.12.004 · Cited by 154
Duda, J., Pötschke, C., & Liss, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13572 · Cited by 154
Breit, S., Bouali‐Benazzouz, R., Benabid, A., & Benazzouz, A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01800.x · Cited by 150
Putzier, I., Kullmann, P. H. M., Horn, J. P., & Levitan, E. S. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-09.2009 · Cited by 148
What causes cell death in Parkinson's disease?
Gupta, A., Dawson, V. L., & Dawson, T. M. (2009) · Annals of Neurology · doi:10.1002/ana.21573 · Cited by 148
A Mitocentric View of Parkinson's Disease
Haelterman, N. A. T., Yoon, W. H., Sandoval, H., Jaiswal, M., Shulman, J. M., & Bellen, H. J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014317 · Cited by 142
Dragicevic, E., Schiemann, J. M., & Liss, B. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.037 · Cited by 141
The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease
Gorenberg, E. L., & Chandra, S. S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00248 · Cited by 140
Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress
Guzmán, J. N., Ilijić, E., Yang, B., Sánchez-Padilla, J., Wokosin, D. L., Galtieri, D. J., Kondapalli, J., Schumacker, P. T., & Surmeier, D. J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95898 · Cited by 137
Self-citationMeredith, G. E., Totterdell, S., Beales, M., & Meshul, C. K. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.06.005 · Cited by 132
Subramaniam, M., Althof, D., Gispert, S., Schwenk, J., Auburger, G. W. J., Kulik, Á., Fakler, B., & Roeper, J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5069-13.2014 · Cited by 129
Endogenous Calcium Buffering Capacity of Substantia Nigral Dopamine Neurons
Foehring, R. C., Zhang, X. F., Lee, J. C. F., & Callaway, J. C. (2009) · Journal of Neurophysiology · doi:10.1152/jn.00038.2009 · Cited by 127
Pedunculopontine-evoked excitation of substantia nigra neurons in the rat
Scarnati, E., Campana, E., & Pacitti, C. (1984) · Brain Research · doi:10.1016/0006-8993(84)90339-1 · Cited by 124
Calcium signaling in Parkinson’s disease
Calí, T., Ottolini, D., & Brini, M. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1866-0 · Cited by 124
Calcineurin determines toxic versus beneficial responses to α-synuclein
Caraveo, G., Auluck, P. K., Whitesell, L. J., Chung, C. Y., Baru, V., Mosharov, E. V., Yan, X., Johny, M. B., Soste, M., Picotti, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413201111 · Cited by 123
Physiological Phenotype and Vulnerability in Parkinson's DiseasePreprint
Surmeier, D. J., Guzmán, J. N., Sánchez, J. A., & Schumacker, P. T. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009290 · Cited by 123
Self-citationMasilamoni, G. J., Bogenpohl, J. W., Alagille, D., Delevich, K. M., Tamagnan, G. D., Votaw, J. R., Wichmann, T., & Smith, Y. (2011) · Brain · doi:10.1093/brain/awr137 · Cited by 119
Diepenbroek, M., Casadei, N., Esmer, H., Saido, T. C., Takano, J., Kahle, P. J., Nixon, R. A., Rao, M. V., Melki, R., Pieri, L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu112 · Cited by 116
Kupsch, A. R., Sautter, J., Schwarz, J., Riederer, P. F., Gerlach, M., & Oertel, W. H. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00917-1 · Cited by 110
Interaction of misfolded proteins and mitochondria in neurodegenerative disorders
Abramov, A. Y., Berezhnov, A. V., Fedotova, E. I., Зинченко, В. П., & Долгачева, Л. П. (2017) · Biochemical Society Transactions · doi:10.1042/bst20170024 · Cited by 109
Brimblecombe, K. R., Gracie, C. J., Platt, N. J., & Cragg, S. J. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.285890 · Cited by 106
Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease
Plotegher, N., & Duchen, M. R. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00110 · Cited by 106
Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study
Lee, Y., Lin, C., Wu, R., Lin, J., Chang, C., & Lai, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098961 · Cited by 105
Heo, J. Y., Park, J. H., Kim, S. J., Seo, K. S., Han, J., Lee, S. H., Kim, J., Park, J., Park, S. K., Lim, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032629 · Cited by 105
Mitochondrial dysfunction associated with glucocerebrosidase deficiency
Gegg, M. E., & Schapira, A. H. V. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.006 · Cited by 98
Genes associated with Parkinson's disease: regulation of autophagy and beyond
Beilina, A. G., & Cookson, M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13266 · Cited by 98
Helwig, M., Klinkenberg, M., Rusconi, R., Musgrove, R. E., Majbour, N. K., El‐Agnaf, O. M. A., Ulusoy, A., & Monte, D. A. D. (2015) · Brain · doi:10.1093/brain/awv376 · Cited by 98
Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury
Ulusoy, A., Musgrove, R. E., Rusconi, R., Klinkenberg, M., Helwig, M., Schneider, A., & Monte, D. A. D. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0198-y · Cited by 93
Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions
Bender, A., Schwarzkopf, R.-M., McMillan, A., Krishnan, K. J., Rieder, G., Neumann, M., Elstner, M., Turnbull, D. M., & Klopstock, T. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0892-9 · Cited by 89
Interactions between Calcium and Alpha-Synuclein in Neurodegeneration
Rcom-H'cheo-Gauthier, A. N., Goodwin, J., & Pountney, D. L. (2014) · Biomolecules · doi:10.3390/biom4030795 · Cited by 86
DJ‐1, PINK1, and their effects on mitochondrial pathways
Cookson, M. (2010) · Movement Disorders · doi:10.1002/mds.22713 · Cited by 85
Mitochondrial Pathology in Parkinson's Disease
Schapira, A. H. V. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20303 · Cited by 83
Litim, N., Morissette, M., & Paolo, T. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.036 · Cited by 82
Kirola, L., Behari, M., Shishir, C., & Thelma, B. K. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.07.014 · Cited by 82
Differential Somatic Ca2+ Channel Profile in Midbrain Dopaminergic Neurons
Philippart, F., Destreel, G., Merino‐Sepúlveda, P., Henny, P., Engel, D., & Seutin, V. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0459-16.2016 · Cited by 73
Proteolysis of α‐synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology
Sacino, A. N., Brooks, M., Chakrabarty, P., Saha, K., Khoshbouei, H., Golde, T. E., & Giasson, B. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13743 · Cited by 72
Deregulation of calcium homeostasis mediates secreted α–synuclein-induced neurotoxicity
Melachroinou, K., Xilouri, M., Emmanouilidou, E., Masgrau, R., Papazafiri, P., Stefanis, L., & Vekrellis, K. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.006 · Cited by 71
A new role for α‐synuclein in Parkinson's disease: Alteration of ER–mitochondrial communication
Guardia‐Laguarta, C., Área-Gómez, E., Schon, E. A., & Przedborski, S. (2015) · Movement Disorders · doi:10.1002/mds.26239 · Cited by 70
Drouet, V., & Lesage, S. (2014) · BioMed Research International · doi:10.1155/2014/289728 · Cited by 67
Dihydropyridine calcium channel blockers and the progression of parkinsonism
Marras, C., Gruneir, A., Rochon, P. A., Wang, X., Anderson, G., Brotchie, J. M., Bell, C. M., Fox, S. H., & Austin, P. C. (2011) · Annals of Neurology · doi:10.1002/ana.22616 · Cited by 65
Singh, A., Verma, P., Balaji, G., Samantaray, S., & Mohanakumar, K. P. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.07.003 · Cited by 60
Vernon, A. C., Zbarsky, V., Datla, K. P., Croucher, M. J., & Dexter, D. T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04860.x · Cited by 55
Benazzouz, A., Piallat, B., Ni, Z., Koudsié, A., Pollak, P., & Benabid, A. (2000) · Cell Transplantation · doi:10.1177/096368970000900207 · Cited by 55
Bach, J., Riedel, O., Klotsche, J., Spottke, A. E., Dodel, R. C., & Wïttchen, H. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.11.002 · Cited by 54
Protection against dopaminergic nigrostriatal cell death by excitatory input ablation
Takada, M., Matsumura, M., Kojima, J., Yamaji, Y., Inase, M., Tokuno, H., Nambu, A., & Imai, H. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00062.x · Cited by 50
Galtieri, D. J., Estep, C. M., Wokosin, D. L., Traynelis, S. F., & Surmeier, D. J. (2017) · eLife · doi:10.7554/elife.30352 · Cited by 49
Self-citationReduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis
Gudala, K., Kanukula, R., & Bansal, D. (2015) · International Journal of Chronic Diseases · doi:10.1155/2015/697404 · Cited by 48
Geng, X., Xie, J., Wang, X., et al. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.02.026 · Cited by 30
Global aging and the brain: Nutrition Reviews©, Vol. 68, No. S2
Kirkwood, T. B. L. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00343.x · Cited by 27
Zhang, Q., Liu, J., Wang, Y., Wang, S., Wu, Z. H., Yan, W., Hui, Y. P., & Ali, U. (2008) · Brain Research · doi:10.1016/j.brainres.2008.09.028 · Cited by 26
Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine
Jain, M. K., & Bhat, R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.004 · Cited by 25
Intracellular Uncaging of cGMP with Blue Light
Agarwal, H. K., Zhai, S., Surmeier, D. J., & Ellis‐Davies, G. C. R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00237 · Cited by 23
Self-citationMutational analysis of SYNJ1 gene (PARK20) in Parkinson's disease in a Taiwanese population
Chen, K.-H. S., Wu, R., Lin, H., Tai, C., & Lin, C. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.009 · Cited by 18
Cited by
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
The mechanisms and roles of selective autophagy in mammals
Vargas, J. N. S., Hamasaki, M., Kawabata, T., Youle, R. J., & Yoshimori, T. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00542-2 · Cited by 1,016
Circuit Mechanisms of Parkinson’s Disease
McGregor, M. M., & Nelson, A. B. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.004 · Cited by 624
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease
Piwecka, M., Rajewsky, N., & Rybak-Wolf, A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00809-y · Cited by 320
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286
Metadata
- Authors
- Surmeier, D. J.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2018-08-14
- Volume
- 285
- Issue
- 19
- Pages
- 3657-3668
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W2884263697
- Cited by
- 444
- References
- 140
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.